FINWIRES · TerminalLIVE
FINWIRES

INmune Bio Reports 'Statistically Significant Treatment Effect' in Phase 2 Alzheimer's Trial

By

INmune Bio (INMB) said Tuesday that a phase 2 clinical trial of its experimental drug XPro1595 demonstrated a "statistically significant treatment effect" on white matter brain biomarkers to treat patients with early onset Alzheimer's disease.

The biotech firm said that while previous studies on Alzheimer's disease have focused heavily on gray matter pathology, white matter degeneration and myelin loss "are increasingly recognized as fundamental, early contributors to cognitive decline."

INmune Bio said the 24-week trial evaluated patients with mild cognitive impairment and mild Alzheimer's dementia.

INmune Bio shares were 1.4% higher in Tuesday trading.

Price: $1.41, Change: $+0.02, Percent Change: +1.44%

Related Articles

Wire

USA Rare Earth Selects South Carolina Site for New Magnet, Metals Facility

USA Rare Earth (USAR) has selected Cherokee County, South Carolina, as the site for a new magnet manufacturing and refined metals facility, the company said Tuesday.The facility will produce sintered neodymium-iron-boron permanent magnets and refined rare earth metals, and once fully operational, it will target an annual production capacity of 6,400 metric tons of magnets and 5,000 metric tons of strip-cast metal, the company said.Engineering work is underway, with site construction starting in the coming months and commissioning targeted for 2028, the company said.Combined with expansions at its Stillwater, Oklahoma, facility, the company expects total domestic capacity to reach 10,000 metric tons per year for both product lines.Shares of USA Rare Earth were up 3.8% in early Tuesday trading.Price: $30.56, Change: $+1.13, Percent Change: +3.82%

$USAR
Wire

Workday Expands AI Platform With New AWS Data Cloud Integration

Workday (WDAY) will integrate its Workday Data Cloud with Amazon Web Services (AMZN), allowing developers to access governed HR and finance data through AWS AI and analytics tools, the company said Tuesday.The integration enables bi-directional, zero-copy access between AWS and Workday's data layer. This is intended to allow customers to use tools like Amazon Bedrock without duplicating data or having to rebuild business logic from scratch, the company said.Workday said its governance, permissions and audit controls will remain embedded across the data environment.Shares of Workday were down nearly 5%, while Amazon shares shed 2.5% in early Tuesday trading.Price: $149.94, Change: $-7.29, Percent Change: -4.64%

$AMZN$WDAY
Wire

Cumberland Pharmaceuticals, Vanderbilt Health Report Positive Phase 2a Results for Ifetroban in Metastasis Prevention Study

Cumberland Pharmaceuticals (CPIX) and Vanderbilt Health reported positive phase 2a results for ifetroban in patients with high-risk solid tumors, with the study meeting its primary endpoint for safety and tolerability, the companies said Tuesday.The randomized placebo-controlled trial evaluated ifetroban in patients at high risk for early metastatic recurrence across multiple cancer types, including breast, lung, pancreatic, soft tissue, bladder, and renal cancers, the companies said.Distant metastatic recurrence occurred in 17% of patients treated with ifetroban, compared with 50% in the placebo arm, while three deaths linked to metastatic disease were reported in the placebo group and none in the ifetroban group, Cumberland Pharmaceuticals and Vanderbilt Health said.Treatment-related adverse event rates were similar between both groups, with no serious treatment-related adverse events identified, the companies said.Shares of Cumberland Pharmaceuticals were 2% lower in early Tuesday trading.Price: $5.58, Change: $-0.12, Percent Change: -2.11%

$CPIX